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Edited by Gerrit van MeerAbstract Drug-induced phospholipidosis is characterized by
intracellular accumulation of phospholipids with lamellar bodies,
most likely from an impaired phospholipid metabolism of the
lysosome. Organs aﬀected by phospholipidosis exhibit inﬂamma-
tory reactions and histopathological changes. Despite signiﬁcant
advances in the understanding of drug-altered lipid metabolism,
the relationship between impaired phospholipid metabolism and
drug-induced toxicity remains enigmatic. Here we review mole-
cular features of inheritable lysosomal storage disorders as a
molecular mimicry of drug-induced phospholipidosis for an im-
proved understanding of adverse drug reaction.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The appearance of microscopic subcellular structures in-
duced by a variety of drugs led to recognition of a disorder
that was subsequently termed drug-induced phospholipidosis
(DIPL) [1]. Ultrastructural investigations revealed that these
cytosolic inclusions consist of concentric myelin-like struc-
tures, the so-called lamellar bodies, the presence of which
became the morphological hallmark of phospholipidosis [2].
Lamellar inclusion bodies are abundant in type II pneumo-
cytes, where they function as storage vesicles and transporter
of surfactant proteins. But in lysosomal storage disorders the
lamellar bodies contain primarily undegraded phospholipids.
Essentially, drug-induced phospholipidosis is characterized
by phospholipid accumulation in aﬀected tissue of which lung,
liver, brain, kidney, cornea and others have been reported [3].
So far, more than 50 novel chemical entities have been iden-
tiﬁed to induce phospholipidosis. These include antibiotics,
antidepressants, antipsychotics, antimalarial and antiarryth-
mic drugs. Many of these are cationic amphiphilic drugs
(CADs) and share particular physical properties resulting from
a chemical structure containing a hydrophilic ring and hydro-
phobic regions. Several of these drugs display severe adverse*Corresponding author. Address: Fraunhofer Institute of Toxicology
and Experimental Medicine, Nikolai-Fuchs-Str. 1, 30625 Hannover,
Germany.
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doi:10.1016/j.febslet.2006.08.061eﬀects, such as acute pneumonitis or hepatitis as observed
under amiodarone treatment [4]. However, the relationship
between drug-induced phospholipidosis and adverse drug
eﬀects remains unexplained. Speciﬁcally, the onset of phospho-
lipidosis may or may not be associated with clinical symptoms,
including inﬂammatory reactions and histopathological
changes, such as macrophagic inﬁltration or ﬁbrosis. Clinically
relevant phospholipidosis has been observed under administra-
tion of amiodarone, ﬂuoxetine, gentamicin, perhexiline and
4.4 0-dieethylaminoethoxyhexestrol [5].
The term drug-induced phospholipidosis ascribes to a condi-
tion that has been deﬁned by the appearance of intracellular
accumulation of phospholipids and lamellar bodies. Beyond
this deﬁnition, each CAD induces its own speciﬁc phospho-
lipid composition and selectively targets organs. There are spe-
cies diﬀerences in drug-induced phospholipidosis and the
presence of lamellar bodies may not always signify drug-
induced phospholipidosis [6]. Animal models and cell culture
systems have been used to study induction of lamellar bodies
in response to several cationic amphiphilic drugs [7]. Essen-
tially, the lysosome seems to be the primary target for drug-in-
duced phospholipidosis and may serve as a storage organelle
for phospholipid accumulation as well. Inhibition of lysosomal
enzymes by CADs decreases phospholipid degradation thereby
rendering lipid-drug particles indigestible [5]. As of today,
drug-induced phospholipidosis remains an unresolved issue
due to unclear molecular causes, and its sporadic relationship
with adverse drug reactions. Indeed, the biological conse-
quences of phospholipid accumulation in targeted organs such
as liver or kidney remain, at least in part, speculative. Here we
focus on drug-induced phospholipidosis, the origin of the
lamellar bodies and its relationship to organ toxicity. Notably,
some basic understanding on the various causes of phospholip-
idosis have been reviewed elsewhere [7,8].2. The lamellar body
The lamellar bodies (also called: lysosomal inclusion bodies or
myeloid bodies) are the pathologic–morphologic hallmark of
phospholipidosis. In aﬀected tissues, lamellar bodies can be
seen by electron microscopy, where they frequently appear as
intracellular concentric structures containing mainly deposits
of undegraded lipids [6] (see also Fig. 1 and explanation herein).
Normally, lamellar bodies serve as storage vesicle of surfactant
in type II pneumocytes and were identiﬁed in pulmonary alve-
olar macrophages. These storage vesicles can be visualized by
the Papanicolaou stain [9]. Lamellar bodies have also beenblished by Elsevier B.V. All rights reserved.
Fig. 1. (A) Lamellar body. (B) Fusion of two lamellar bodies inside the hepatocyte (* collagen ﬁbres in the space of disse). (C) Hyperplasia of the
endoplasmic reticulum during phospholipidosis. (D) Phagocytosis of lamellar bodies by Kupﬀer cells in the sinusoidal space. (E) Several lamellar
bodies are located intracellular inside a hepatocyte that displays a high grade of vacuolization. (F) A Kupﬀer cell loaded with lipid droplets close to a
disintegrated hepatocyte on the bottom of the picture. (G) In contrast, lipid droplets characterizing the steatosis.
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gastric mucosa, in the peritoneum as well as pleural mesothe-
lium [10]. In pathological conditions, however, these concentric
bodies are typical for lysosomal storage disorders, such as the
Niemann–Pick disease type I as well as drug-induced phospho-
lipidosis. Furthermore, lamellar bodies are observed in cases of
acute respiratory distress syndrome (ARDS) and in lecithin:
cholesterol acyltransferase (LCAT) deﬁciency [11].
From the physiological context in which lamellar bodies
arise, it is clear that they are somehow connected to biosynthe-
sis and turnover of lipids. As mentioned above, lamellar bodies
may serve as storage vesicles of surfactant or glucosylceramide,
which is a precursor of ceramides and part of the epidermal
permeability barrier. By topographic co-localization of lyso-
somal enzymes, the origin of lamellar body may be traced back
to the lysosome. In addition, drug-induced lamellar bodies
were shown to retain their fusion capabilities after drug with-
drawal, which also supports a lysosomal origin [6].
Two principal hypotheses have been put forward to explain
the formation of lamellar bodies, which typically consist of a
lamellar core surrounded by a membrane (see Fig. 1). Indeed,
Landmann described lamellar bodies as derived from mem-
brane ﬁssion or budding of the trans-Golgi network to result
in an unilamellar vesicle, that holds stacks of multiple ﬂattened
unilamellar vesicles (lamellar body-disks) [12]. This proposal
has been criticized for its high energy requirement in the pro-
cess of membrane fragmentation. In strong contrast, Norle´n
proposed a three-dimensional lipid structure model that con-
sists of a separating outer cubic-like folded membrane with a
larger lattice parameter and a single inner highly curved mem-brane, which corresponds to the lamellar structure of the inclu-
sion bodies [13].
Despite uncertainties about origin and production of lamel-
lar bodies and the varying circumstances in which they might
appear, it is likely that lamellar bodies do not represent a
homogenous entity; indeed, they display a broad spectrum
amongst diﬀerent species and organs. Speciﬁcally, their size
varies between 100 and 2400 nm, they may appear uni- or mul-
ti-centred, contain apolipoproteins and have an acidic charac-
ter, as observed in the lysosome [6]. Four functional types of
lamellar bodies have been proposed by Schmitz and Mu¨ller
deriving from either extracellular secretion (i), intracellular
lipid storage (ii) extracellular origin, such as plasma lipid
derived particles found in lecithin:cholesterol acetyltransferase
(LCAT) deﬁciency (iii) or pathologic accumulation of extracel-
lular membrane (iv). It is known that lamellar bodies may con-
tain diﬀerent phospholipids, their source, however, is still
unidentiﬁed and may be generated during autophagic or het-
erophagic processes. Furthermore, strong evidence suggests
involvement of the endoplasmic reticulum in the formation
of lamellar bodies during autophagy [10].
Notably, cationic amphiphilic drugs were shown to bind
phospholipids and to induce formation of aggregated
phospholipid particles under certain circumstances [14].
Even though CADs were shown to induce phospholipidosis,
the cationic amphiphilic moiety alone may not be the sole
requirement for induction of multilamellar inclusions in DIPL.
For instance, the amphiphilic b-adrenergic drugs atenolol
and sotalol and the local anesthetic and K+ channel inhibitor
procainamide showed no induction of lamellar body inclusion,
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trol [15].3. The lysosome in relation to drug-induced phospholipidosis
Even though phospholipidosis has been investigated exten-
sively, no unifying mechanistic explanation has been put for-
ward. Likely, the way by which amphiphilic drugs interact
with the lysosomal system aﬀects multiple pathways as detailed
below.
The lysosome is part of the endosomal–lysosomal system,
which was ﬁrst discovered by Cristian De Duve in 1955 [16].
This cellular subcompartment is surrounded by a phospholipid
bilayer and allows to maintain a v-type H+-ATPase generated
acidic milieu [17].
Approximately 40 diﬀerent hydrolytic enzymes, including
proteases, nucleases, glycosidases, lipases, phospholipases,
proteases, phosphatases, sulfatases and several proteins of yet
unknown function have been identiﬁed to composite the
lysosomal content [18]. The hydrolyzing enzymes that have been
contributed in formofproenzymes in vesicles of the endoplasmic
reticulum (ER) andGolgi apparatus are activated by the low pH
and are responsible for degradation of internalized micro- and
macrophagic particles. These functions are termed endocytosis
(heterophagy) or autophagy and describe connected lysosomal
pathways inwhich either exogenous particles (such as cell debris,
receptor-substrate complexes, etc.) or cytoplasmic constituents
are aﬃliated and stored or recycled. The exocytotic activities
of the lysosome play an important role in cell membrane repair
and secretion of exogenous substances [19].
The lysosomal functions reach far beyond the recycling of
cellular organelles and macromolecules. For instance, a group
of lysosomal enzymes, the cathepsin proteases, play a crucial
role in cell cycle control and antigen presentation. Their inﬂu-
ence on cell motility, invasion and angiogenesis is mediated by
degradation of extracellular matrix and has become a major
focus of cancer-related research [20]. Lysosomal autophagy
has been discussed as both an alternative non-apoptotic form
of programmed cell death and a survival strategy during lean
times. The role of autophagy and apoptosis in cell death and
cell growth control needs to be further investigated, but the
evidence available implies that alterations in the functioning
of the lysosome may ascribe a signiﬁcant participation during
pathologic events [21].4. CADs interact with phospholipids
Unlike hereditary lysosomal storage disorders, in which spe-
ciﬁc gene defects impair lysosomal function, drug-induced
phospholipidosis is believed to result from several events
caused by direct interaction of cationic amphiphilic drugs with
phospholipids [8]. This assumption is based on two observa-
tions: Firstly, during phospholipidosis an accumulation of
amphiphilic drugs in lysosomes is observed [5]. The strong
aﬃnity of drugs for the lysosomal compartment has been
termed lysosomotropic behaviour [22]. Speciﬁcally, the aﬃnity
of cationic amphiphilic drugs can be explained by the acidic
milieu of the lysosome and the weak basic properties of several
xenobiotics. Chloroquine, for instance, is a weak base that isprotonated after entering the low pH of the lysosome. The ion-
ized form of the drug cannot pass through the hydrophobic
core of the phospholipid bilayer that surrounds the lysosomal
compartment and is therefore trapped [7]. Furthermore, the
basic moieties of CADs raise the lysosomal pH, which coin-
cides with phospholipidosis, but this eﬀect occurs only tempo-
rarily and therefore may not represent a mechanism in the
development of phospholipidosis [23]. Note, some CADs accu-
mulate by lysosomal entrapment to result in high intralysoso-
mal drug concentrations. In the case of treatment with
aminoglycosides increases in lysosomal permeability were ob-
served and coincided with activation of caspase-3 in kidney
displaying phospholipidosis [24]. Next to diﬀusion, active up-
take mediated by glycoreceptors into the lysosome has been
proposed as a molecular avenue for lysosomal entrapment.
Apparently, gentamicin-induced damage in the renal proximal
tube is mediated speciﬁcally by megalin and when bound by
this antibiotic the fusion of endosomes was inhibited [25]. It
was demonstrated that uptake of cationic amphiphilic drugs
into the lysosome correlates with therapeutic plasma concen-
trations [26,27]. Furthermore, even at low doses certain CADs
can cause lysosomal alterations in cultured ﬁbroblasts [28].
Redistribution of CADs after vitamin E administration is a
mechanism believed to be responsible for the reversing eﬀect
of alpha-Tocopherol (alpha-Toc) on phospholipidosis [29].
Secondly, drug-induced phospholipidosis may arise from di-
rect interaction of amphiphilic drugs with phospholipids [5].
For instance, chlorpromazine interacts with phospholipid
membranes in a non-speciﬁc way, that increases membrane ﬂu-
idity and enhances the release of neurotransmitters, thereby
originating its therapeutic eﬀect [30]. On the other hand, amio-
darone positions in the hydrophobic core of the lipid bilayer
where it alters the lipid dynamics. These interactions are
believed to aﬀect ion transport and oxidative phosphorylation
that have been observed under amiodarone treatment [5]. The
interactions of amphiphilic drugs and phospholipid bilayers
are not homogenous [31]. A comparison of binding character-
istics of several CADs to phosphatidylcholine revealed major
diﬀerences. Indeed, while amiodarone was bound to the hydro-
phobic part, chlorphentermine and gentamicin displayed a
strong aﬃnity for the hydrophilic part, whereas chloroquine
did not bind to either site of the phospholipid molecule [5].
The potency of an amphiphilic drug to induce phospholipidosis
has been reported to correlate positively with the strength of its
drug/phospholipid interactions [32,33]. Alterations in pH, pKa,
ion charge and hydrophobic properties of the lipid bilayer
or partition coeﬃcient may induce changes in the interaction
between the drug and the phospholipid [5] and are therefore
drivers of lysosomal entrapment of CADs [26].5. Molecular mechanisms of drug-induced phospholipidosis
Basically two hypotheses have been put forward to explain
the underlying mechanisms of drug-induced phospholipidosis
[8]. The ﬁrst hypothesis assumes that CADs bind directly to
phospholipids to result in indigestible drug–lipid complexes,
which accumulate and are stored in the form of lysosomal
lamellar bodies [7]. The second hypothesis is based on the
observation that production of lamellar bodies was associated
with inhibition of phospholipase activity; either due to direct
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the lysosome [8].
Lysosomal phospholipases play a critical role in the degra-
dation of cellular membranes [34]. Speciﬁcally, phospholipase
A1 (PLA1), Ca2+ dependent and independent phospholipase
A2, and calcium-dependent phospholipase C were shown to
be inhibited in a dose-dependent fashion by chlorpromazine,
amiodarone and chloroquine. Furthermore, chlorpromazine,
propanolol and chloroquine were found to mediate inhibition
of phospholipase C activity by direct binding to the enzyme.
The aﬃnity for phospholipase A2 and its competitive inhibi-
tion has been variable among diﬀerent amphiphilic substances
[5]. Other lysosomal enzyme activities have been modulated by
amphiphilic drugs, notably activity of the cathepsin B protease
[35]. Enhanced activities of the lysosomal hexosaminidase, acid
sphingomyelinase and sulfatase B in cells of the kidney cortex
are considered to be compensatory increases of degrading
enzymes due to phospholipase inhibition [36]. Interestingly,
decreased sphingomyelinase activity was reported for cells of
the renal cortex after gentamicin application [37]. Further-
more, chlorphentermine and gentamicin were shown to inhibit
phospholiase C. While gentamicin inhibited the phosphatidyl-
choline and phosphatidylserine speciﬁc variants of phospho-
lipase C, chlorphentermine inhibited a phosphatidylinositol
speciﬁc phospholipase C [38].
Another possible mechanism for interference of CADs with
phospholipase activity was proposed by Mingeot-Leclercq and
co-workers, who had raised the negative charge hypothesis, by
which phospholipase A1 inhibition resulted from charge neu-
tralization of the lysosomal phospholipid bilayer [39,40]. This
assumption was supported by studies with the erythromycin A
derivative, azithromycin and the aminoglycoside gentamicin
[39,41].
Recently, Piret et al. [42] reported that the activity of phos-
pholipase A1 is, in fact, inﬂuenced by the charged contents of
the phospholipid bilayer. Increasing concentrations of nega-
tively-charged lipids markedly enhanced activity of the phos-
pholipase A. These ﬁndings are in support of the neutral
charge hypothesis. Furthermore, secondary inhibition of phos-
pholipase A1 could result from the accumulation of lysosomal
phospholipids that inﬂuence the charge of the lysosomal
bilayer in favour of neutral lipids.
It is of considerable importance that phospholipidosis is
reversible to a certain point after withdrawal of the drug as
demonstrated successfully in vitro, in vivo and clinically
[43,44]. There are cases of phospholipidosis, however, where
inhibition of lysosomal phospholipase A2 or sphingomyelinase
persists [45]. Take note, that phospholipidosis was shown to
occur within hours in cell culture experiments or after several
months of treatment. Furthermore, the severity and organ/tis-
sue speciﬁcity of phospholipidosis diﬀered amongst drugs, but
correlated with increased drug plasma concentrations. Like-
wise, the composition of accumulated phospholipids in phos-
pholipidosis diﬀer amongst drugs [5].6. Phospholipidosis – a defence mechanism of the cell?
The biological consequence of phospholipid accumulations
in several organs has not been evaluated to a point where lyso-
somal phospholipid storage and consecutive lysosomal dys-
function could clearly be linked to cellular toxicity. However,in vivo and in vitro investigations have given insights by which
phospholipidosis does aﬀect cellular function. After all, lyso-
somal protein degradation, fusion abilities, pino- and endo-
cytosis have been impaired after CAD administration [8].
Furthermore, alveolar macrophages have the ability to scav-
enge lamellar bodies, which when completely packed become
foamy macrophages during drug-induced phospholipidosis of
the lung. Pulmonary macrophages have been studied inten-
sively for functional consequences of phospholipidosis associ-
ated with the presence of lamellar bodies [46]. Enhanced
phagocytic activity in pulmonary macrophages together with
an increased production of bactericidal oxygen radicals might
imply a shift of the immune response towards an enhanced
unspeciﬁc cellular (phagocytic) response [47]. Indeed, the hu-
moral immune response and in particular the delayed hyper-
sensitivity response, the ability to activate antibody-secreting
cells and the blastogenic response were signiﬁcantly depressed
after chlorphentermine administration in animal models [48].
This shift might suggest a defence mechanism of the cell when
confronted with xenobiotics and their metabolites which other-
wise would compromise the integrity of the cell.
Therefore, phospholipidosis might also be a part of a novel
detoxiﬁcation mechanism to prevent the cell from amphiphilic
xenobiotics. Herein, the central role of the lysosome could lie
in an activation of a cell survival strategy based on autophagy
[21].
Lamellar bodies induced by phospholipidosis, have been ob-
served to undergo exocytosis and have been located in the
extracellular space. The images obtained by the electron
microscopy are depicted in Fig. 1 demonstrate a hepatocyte
releasing a lamellar body via exocytosis into the hepatic sinu-
soid during xenobiotic-induced phospholipidosis.
Notably, the Figure depicts phospholipidosis upon treat-
ment of rats with Aroclor 1254, a mixture of polychlorinated
biphenyls. This treatment resulted in steatosis, hyperplasia of
endoplasmic reticulum and formation of lamellar bodies. Fur-
thermore, scavenging of lipid droplets and lamellar bodies by
Kupﬀer cells is documented.
Indeed, due to entrapment, CADs exert theirmajor impact in-
side the lysosomal compartment. As long as the drug is conﬁned
to the lysosome, cells may be protected from toxicity. If so, inhi-
bition of lysosomal enzyme activity could be a secondary eﬀect.
Thus, phospholipidosis could be part of a defence mechanism
by which phospholipid recycle stacks accumulate, which enhar-
bour a toxic xenobiotic [49]. By releasing the lamellar bodies via
exocytosis, the cell bypasses excessive oxidation, detoxiﬁcation
and production of ROS (reactive oxygen species) thereby pre-
venting undue stress. Cells of the macrophage system, such as
the pulmonary macrophages and the Kupﬀer cells of the liver,
scavenge the lamellar bodies and facilitate their removal for
further clearance of the lamellar body/xenobiotic complex.
Enhanced lysosomal enzyme release and a dose-dependent
clearance of CADs into the bile may be suggestive for an
enhanced exocytotic activity [50]. It is probable, that suchmech-
anism is limited to certain drugs and may be saturable. Once a
drug exceeds certain concentrations, lysosomal permeability is
a likely event [51]. For instance, apoptosis, mitochondrial swell-
ing and lactate dehydrogenase (LDH)-release during phospho-
lipidosis has been reported for the proximal renal tubular cells
upon treatment with aminoglycosides [24].
Take note, that aminoglycosides cause acute renal toxicity
due to tubular necrosis. Several factors have been suggested
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bition and peroxidation of phospholipids [24]. Furthermore,
secondary eﬀects of increased cellular phospholipid, e.g., inhi-
bition of protein synthesis, inhibition of phospholipase C as
well as an impairment of protein kinase C have been discussed
[8]. Indeed, neither phospholipase inhibition nor phospholipid
accumulation alone resulted in cell toxicity, but the nephropro-
tective eﬀect of polyaspartic acid administration had brought
phospholipidosis back to the centre of discussion. Polyaspartic
acid is transported to the lysosome via endocytosis and builds
complexes with the aminoglycosides gentamicin or amikacin.
In such complexes aminoglycosides were stored in a non-toxic
form and prevented interaction with phospholipids [24].
Aminoglycosides display a broad range in their potency to in-
duce apoptosis and interference with the mitochondrial elec-
tron transport [24]. The role of phospholipidosis in this
toxicity remains speculative [52]. As of today, only a few cases
of toxicity induced by cationic amphiphilic drugs could be
directly linked to phospholipidosis [8], but the b-blocker pro-
pranolol and the Ca2+-antagonist verapamil were shown to
decrease mitochondrial volume density associated with a
signiﬁcant dose-dependent LDH-release in hepatocytes at sub-
toxic concentrations [15]. Recently, amiodarone and imipra-
mine were shown to inhibit cell proliferation and to activate
caspase-mediated apoptosis in cell culture [53].7. Learning from lysosomal storage diseases for an improved
understanding of drug-induced phospholipidosis
Lysosomal dysfunctions have been studied in various herita-
ble lysosomal storage diseases including mucopolysacchari-
doses, sphingolipidoses, e.g., the Gaucher‘s disease, and
others, namely the Niemann–Pick type C disease. It is of con-
siderable importance that the disease phenotypes are heteroge-
neous, aﬄict multiple organ systems and are always
progressive. A variety of lysosomal defects thus lead to high
accumulations of lysosomal substrates. For the majority of
lysosomal storage disorders (LSD), the exact pathophysiolog-
ical mechanisms remain unclear. Several mutations have been
identiﬁed in the open reading frames of genes coding for lyso-
somal hydrolases to aﬀect synthesis, folding, activation or tar-
geting of substrates. Furthermore, membrane protein defects
and impaired transport processes have been observed.
The classic lysosomal storage disorder is monogenic and
causes accumulation of lysosomal substrate due to defective
enzymes or proteins. A defective lysosomal hydrolase, for
instance, is found in the neurogenerative Tay-Sachs disease,
where impaired function of the b-hexaminidase A leads to
accumulation of GM2 gangliosides and glycolipids.
Once again, mutations in genes that encode for enzymes can
lead to a variety of deﬁciencies, including undue post transla-
tional modiﬁcations. This has been observed in diﬀerent multi-
ple sulphatase deﬁciencies (MSD) [54].
In Fabry’s disease, deﬁciency of the galactosidase A results
in accumulation of globostriasyl-ceramide. Interestingly, a re-
cent report compared the pathology of chloroquine-induced
phospholipidosis and the Fabry’s disease. The anti-malarial
and anti-rheumatic drug chloroquine is a potent inhibitor of
the lysosomal phospholipase A and C, believed to be responsi-
ble for impaired phospholipid degradation and accumulation.
Note, chloroquine was also shown to reduce activity of the a-galactosidase A. Both Fabry’s disease and chloroquine-in-
duced phospholipidosis induced a similar pattern of inclusion
bodies, speciﬁcally, in renal cells, endothelial cells and striated
myocardial muscle cells. Furthermore, in patients of Fabry’s
disease and in chloroquine-induced phospholipidosis the
clinical manifestations were similar, e.g., decreased renal func-
tion associated with glomerular proteinuria and edema, which
can be explained by secondary eﬀects of excessive lysosomal
storage and sensitivity to a-galactosidase A deﬁciency [55].
Despite diﬀerent genetic causes the subcellular phenotypes of
inheritable lysosomal storage diseases are similar and fre-
quently due to substrate overload. Furthermore, it was
hypothesized that accumulation of one lipid raft would lead
to trapping of other lipids within the lysosome [57]. For in-
stance, the Niemann–Pick disease type C (NPC) results from
a defect of cholesterol traﬃcking due to a defective NPC-1
protein that is involved in cholesterol transport from the late
endosomes and lysosomes to other organelles. In patients diag-
nosed with NPC, a wide range of neurological symptoms can
be observed. These symptoms, seem however not to arise from
accumulation of cholesterol, but from accumulation of glyco-
sphingolipids (GM2) [58]. Therefore, despite impaired choles-
terol transport in Niemann–Pick disease, type C sphingolipid
accumulation occurs as well. Likewise in Niemann–Pick dis-
ease type A, a defect of the sphingomyelinase leads to accumu-
lation of sphingomyelin that is accompanied by accumulation
of cholesterol. It is of considerable importance that in drug-
induced phospholipidosis, accumulation of phospholipids in
lamellar bodies is also accompanied by increased levels of
neutral lipids and cholesterol. [59] In addition, second raft
accumulation is also expected to alter the membranes of the
endosomal/lysosomal system and to contribute to the forma-
tion of lamellar bodies in lysosomal storage diseases by ﬂatten-
ing the highly curved internal membrane [57].
Changes of the cellular cholesterol turnover are sensored by
the sterol regulatory element binding proteins (SREBP) type
transcription factors and posttranslational by proteins that
contain a sterol sensing domain (SSD), such as the NPC-1 pro-
tein and the HMG-CoA reductase [60]. Speciﬁcally, the
SREBPs regulate multiple genes of the cholesterol biosynthesis
and uptake pathway, including the HMG-CoA reductase and
HMG-CoA synthase [61]. It is of considerable interest that in a
recent toxicogenomic study the majority of drugs tested for
their potency to induce phospholipidosis provoked transcrip-
tional upregulation of HMG-CoA reductase and HMG-CoA
synthase [62].
Furthermore, the HMG-CoA reductase is embedded in the
membrane of the endoplasmic reticulum and was shown to
increase intracellular cholesterol, which triggered the unfolded
protein response in macrophages [56]. Likely, lipid overload of
the lysosome contributed to the advancement of drug-induced
phospholipidosis.
The genomic response to phospholipidosis includes attenua-
tion of transcription of several genes coding for lipid metabo-
lism and transport, such as the ELOVL (elongation of long
chain fatty acids) family member 6 and the FABP (fatty acid
binding protein) [62].
An impairment of lysosomal lipid transport has also been
suggested to be involved in the pathology of NPC and in the
formation of lamellar bodies in respiratory distress syndrome
(RDS). The ATP-binding cassette (ABC) transporter A1
(ABCA1) ABCA1 mediates the rate-limiting step in high
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regulated by cellular cholesterol. Impairment of this enzyme
was shown to be responsible for an impaired lipid eﬄux in Nie-
mann–Pick disease type C [63]. Formation of lamellar bodies
in fatal respiratory distress syndrome (RDS) in the newborn
has been linked to mutations of the ABCA3. The ABCA3 gene
is exclusively expressed in the lung, speciﬁcally in type II cells
and responsible for transport of surfactant protein A. Knock-
down of endogenous ABCA3 caused formation of abnormal
lamellar bodies, while the vesicular uptake of phosphatidyl-
choline, sphingomyelin and cholesterol but not phosphatidyl-
ethanolamine was decreased [64].
Besides, the distinct pathology of some lysosomal storage dis-
eases result from decreasing lysosomal stability, as suggested
elsewhere [54]. Indeed, accumulation of undegraded lipid sub-
strates might cause instability or rupture of the lysosomal mem-
brane above a certain threshold and thus results in leakage of
lysosomal hydrolases into the cytoplasm [54].
The involvement of lysosomal proteases in apoptotic pro-
cesses has been described earlier in this review. Indeed, apop-
tosis of renal cells due to aminoglycosides was shown to be
associated with decreasing lysosomal stability and leakage
[52], where as chlorphentermine was shown to stabilize the
lysosomal membrane in alveolar macrophages during animal
studies [65]. Therefore, drugs diﬀer in their ability to interfere
with the lysosomal membrane.
An investigation of hereditary lysosomal storage disorders
revealed the importance of secondary eﬀects due to accumula-
tion of material within the lysosome for the actual pathology
of the phenotype [66]. For instance, inﬂammatory response
and macrophages activation was shown to be responsible for
the major neuronal damage in Sandhoﬀ’s disease, a lysosomal
storage disorder characterized by storage of gangliosides in
the central nervous system [67]. Macrophage activation is
observed in many lysosomal storage disorders and also in pul-
monary drug-induced phospholipidosis. In Gaucher’s disease,
for instance, in which lysosomal glycolipid storage occurs,
macrophage inﬁltration was reported in association with pro-
teinuria [68]. Recently, the presence of prominent histiocytes
in association with lysosomal inclusions in glomerular capil-
lary lumina have been described as distinct features of chloro-
quine-induced renal damage [55]. Next to lysosomal substrate
accumulation, impaired mitochondrial function was observed
in neuronal ceroid lipofuscinosis and in cells from patients
with Fabry’s disease [66]. Correspondingly, a loss of mitochon-
drial function accompanied by loss of cell viability was
detected in pulmonary phospholipidosis induced by chlorphen-
termine and amiodarone [69,70].
In summary, secondary eﬀects of increased lysosomal stor-
age found in both LSD and DIPL, include changes of lipid
synthesis and traﬃcking, macrophage activation and impaired
mitochondrial function. Even though the pathophysiology of
lysosomal storage disease has not been completely understood,
the study of distinct phenotypes may help to gain mechanistic
insight into drug-induced phospholipidosis.8. Conclusion
Drug-induced phospholipidosis presents an unresolved con-
dition that occurs frequently with a wide range of drugs. Eventhough much eﬀort has been spent to investigate the molecular
eﬀects and functional consequences of drug-induced phospho-
lipidosis, the mechanistic link to adverse drug reactions is
unresolved. Therefore, the causality of phospholipid accumu-
lation, as well as the occurrence of lamellar bodies as a conse-
quence for organelle dysfunction and organ toxicity, remain
enigmatic. An improved understanding of phospholipidosis
will result from genomic analysis, where several drugs known
to cause phospholipidosis induced multiple gene expressions
coding for proteins of the lysosomal integrity and function.
Among them, 12 genes could be classiﬁed in four functional
categories that are involved in downregulated phospholipase
activity and lysosomal enzyme transport as well as upregula-
tion of cholesterol and phospholipid synthesis [62].
It remains unclear whether phospholipidosis may arise from
impaired lysosomal enzyme activities or formation of indigest-
ible CAD–phospholipid complexes. Furthermore, altered lipid
concentrations in phospholipidosis may originate from
increased phospholipid synthesis, decreased degradation or
impaired transport of phospholipids. All of these possibilities
have been associated with phospholipidosis, but neither the
sequence in which they appear, nor their molecular causes
have been elucidated suﬃciently, as yet.
Individual sensitivity may be a determining factor for phos-
pholipidosis and a unifying hypothesis for phospholipidosis by
interference with cationic amphiphilic drugs can not be put
forward [7]. Emerging evidence is suggestive for phospholipi-
dosis to protect cells from undue stress, at least in part, by drug
removal and clearance of lamellar bodies which enharbour li-
pid–drug complexes [71]. Results from investigations into lyso-
somal storage diseases may direct future research in DIPL by
focusing on lysosomal eﬀects of phospholipid storage and, in
particular, changes in gene expression, lysosomal signalling
pathways and lipid metabolism as well as its traﬃcking. Likely,
these studies will permit dissection of altered lipid metabolism,
secondary eﬀects of phospholipid accumulation and eﬀects
linked to adverse drug reactions [62,72].References
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